Home Cart Sign in  
Chemical Structure| 606-58-6 Chemical Structure| 606-58-6

Structure of Toyocamycin
CAS No.: 606-58-6

Chemical Structure| 606-58-6

Toyocamycin

CAS No.: 606-58-6

Toyocamycin is isolated from a culture broth of an Actinomycete strain. It inhibited ER stress-induced XBP1 activation. Toyocamycin suppressed thapsigargin-, tunicamycin- and 2-deoxyglucose-induced XBP1 mRNA splicing in HeLa cells without affecting activating transcription factor 6 (ATF6) and PKR-like ER kinase (PERK) activation.

Synonyms: Vengicide

4.5 *For Research Use Only !

Cat. No.: A178051 Purity: 98% LCMS

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łËÿ¶ÊÊ Inquiry Inquiry
5mg ł§ò¶ÊÊ Inquiry Inquiry
10mg łÿÿ¶ÊÊ Inquiry Inquiry
50mg łÇîǶÊÊ Inquiry Inquiry
100mg ł§§Ê¶ÊÊ Inquiry Inquiry
250mg łó˧¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1mg

    łËÿ¶ÊÊ

  • 5mg

    ł§ò¶ÊÊ

  • 10mg

    łÿÿ¶ÊÊ

  • 50mg

    łÇîǶÊÊ

  • 100mg

    ł§§Ê¶ÊÊ

  • 250mg

    łó˧¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Toyocamycin

CAS No. :606-58-6
Formula : C12H13N5O4
M.W : 291.26
SMILES Code : O[C@H]1[C@H](N2C=C(C#N)C3=C(N)N=CN=C32)O[C@H](CO)[C@H]1O
Synonyms :
Vengicide
MDL No. :MFCD00866513

Safety of Toyocamycin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT116 cells 250 nM 24 hours Induced GFP expression and caused gene expression changes Cancers (Basel). 2022 Jul 8;14(14):3340
HeLa/XBP1-luc cells 0.08 µM 24 hours Inhibition of thapsigargin-induced XBP1-luciferase activation Blood Cancer J. 2012 Jul;2(7):e79
Mature mouse oligodendrocytes (mOLs) 0.05 µM 24 hours To evaluate the effect of Toyocamycin on the survival of mature oligodendrocytes. Results showed a dose-dependent decrease in the viability of mOLs treated with Toyocamycin. Glia. 2021 Feb;69(2):424-435
HEK293T cells 10 µM 24 hours Test the inhibitory effect of Toyocamycin on ribozyme self-cleavage RNA. 2006 May;12(5):797-806
Saccharomyces cerevisiae W303-1A 2.8-70 µM 24 hours Assess the growth inhibitory effect of TM on S. cerevisiae expressing CaCNT. Microbiol Spectr. 2022 Aug 31;10(4):e0113822
Candida albicans SC5314 1.25-10 µM 24 hours Evaluate the growth inhibitory effect of TM on C. albicans, with an estimated IC50 between 1.25-2.5 μM. Microbiol Spectr. 2022 Aug 31;10(4):e0113822
L cells 0.3 µg/ml 2-8 hours Toyocamycin treatment caused the gradual disappearance of the fibrillar zones of nucleoli, resulting in a homogeneous granular appearance. J Cell Biol. 1971 Jun;49(3):803-15
KB cells 0.3 µg/ml 2-8 hours Toyocamycin treatment caused the gradual disappearance of the fibrillar zones of nucleoli, resulting in a homogeneous granular appearance. J Cell Biol. 1971 Jun;49(3):803-15
HeLa cells 0.18 µM 4 hours Inhibition of thapsigargin-induced endogenous XBP1 mRNA splicing Blood Cancer J. 2012 Jul;2(7):e79
S2 cells 100 nM 48 hours Toyocamycin significantly inhibited the relative cell viability and colony-forming ability of IPW-low DCIS cells Breast Cancer Res. 2022 Jan 25;24(1):6
HEK79 cells 1 µM 48 hours Inhibit ribozyme self-cleavage and induce luciferase expression RNA. 2006 May;12(5):797-806
RPMI8226 cells 0.1 µM 6 hours Reduction in the levels of spliced-XBP1 Blood Cancer J. 2012 Jul;2(7):e79
SUM225 cells 100 nM 48 hours Toyocamycin significantly inhibited the relative cell viability and colony-forming ability of IPW-low DCIS cells Breast Cancer Res. 2022 Jan 25;24(1):6
DCIS.com cells 100 nM 48 hours Toyocamycin significantly inhibited the relative cell viability and colony-forming ability of IPW-low DCIS cells Breast Cancer Res. 2022 Jan 25;24(1):6
YB5 cells 5 µM 72 hours Induced GFP expression, with over 60% of YB5 cells expressing GFP Cancers (Basel). 2022 Jul 8;14(14):3340
Mouse oligodendrocyte progenitor cells (mOPCs) 0.05 µM 8 hours To investigate the inhibitory effect of Toyocamycin on Xbp1 splicing and its impact on ERSR. Results showed that Toyocamycin reduced transcript levels of Xbp1s and its downstream targets ERdj4 and Edem, while upregulating pro-apoptotic ISR genes Chop and Gadd34. Glia. 2021 Feb;69(2):424-435

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID mice Human multiple myeloma xenograft model Intraperitoneal injection 0.5 mg/kg or 1.0 mg/kg Twice weekly or once weekly for 2 weeks Evaluation of anti-tumor activity of toyocamycin in a human multiple myeloma xenograft model Blood Cancer J. 2012 Jul;2(7):e79
Nude mice DCIS.com cell implantation model Intraperitoneal injection 2 mg/kg Once a week until the experimental endpoint Toyocamycin significantly suppressed the tumor growth of DCIS.com cells in vivo Breast Cancer Res. 2022 Jan 25;24(1):6
Nude mice AAV vector carrying ribozyme-controlled luciferase reporter gene Subcutaneous injection 20 μM Toyocamycin and 12 μM FUR Single injection Validate the inhibitory effect of Toyocamycin and FUR combination on ribozyme self-cleavage in vivo RNA. 2006 May;12(5):797-806

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.43mL

0.69mL

0.34mL

17.17mL

3.43mL

1.72mL

34.33mL

6.87mL

3.43mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories